Johnson & Johnson (NYSE:JNJ) Position Lifted by SYM FINANCIAL Corp

SYM FINANCIAL Corp raised its stake in Johnson & Johnson (NYSE:JNJ) by 45.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 6,815 shares of the company’s stock after purchasing an additional 2,126 shares during the period. SYM FINANCIAL Corp’s holdings in Johnson & Johnson were worth $996,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Innealta Capital LLC bought a new position in Johnson & Johnson during the second quarter worth $27,000. Christopher J. Hasenberg Inc bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $31,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $44,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $43,000. Finally, Grayhawk Investment Strategies Inc. raised its stake in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, September 9th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $165.52 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm has a market cap of $398.45 billion, a P/E ratio of 10.32, a PEG ratio of 2.71 and a beta of 0.53. The stock has a fifty day moving average price of $159.55 and a two-hundred day moving average price of $153.99. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.